MCID: NRR001
MIFTS: 42

Neuroretinitis

Categories: Neuronal diseases

Aliases & Classifications for Neuroretinitis

MalaCards integrated aliases for Neuroretinitis:

Name: Neuroretinitis 12 15 71
Juxtapapillary Focal Retinitis and Retinochoroiditis 12 71
Retinitis 43 71
Focal Retinitis and Retinochoroiditis, Juxtapapillary 12
Papilloretinitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10176
MeSH 43 D012173
SNOMED-CT 67 410471004
ICD10 32 H30.9
UMLS 71 C0035333 C0154874 C3665438

Summaries for Neuroretinitis

MalaCards based summary : Neuroretinitis, also known as juxtapapillary focal retinitis and retinochoroiditis, is related to central retinal artery occlusion and macular dystrophy, dominant cystoid. An important gene associated with Neuroretinitis is CD40LG (CD40 Ligand), and among its related pathways/superpathways is Visual Cycle in Retinal Rods. The drugs Prednisone and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and testes.

Wikipedia : 74 Cat-scratch disease (CSD) is an infectious disease that most often results from a scratch or bite of a... more...

Related Diseases for Neuroretinitis

Diseases related to Neuroretinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3023)
# Related Disease Score Top Affiliating Genes
1 central retinal artery occlusion 34.1 CRP CD40LG
2 macular dystrophy, dominant cystoid 32.8 RCVRN MRAP ACE
3 fundus dystrophy 31.5 TRPM1 SAG RCVRN MRAP
4 congenital stationary night blindness 31.4 TRPM1 SAG RCVRN
5 acquired night blindness 31.4 TRPM1 RCVRN
6 background diabetic retinopathy 30.8 CRP ACE
7 cancer-associated retinopathy 30.8 SAG RCVRN
8 acquired immunodeficiency syndrome 30.6 CRP CD40LG CD4
9 macular retinal edema 30.5 MRAP ACE
10 scleritis 30.4 MRAP CRP
11 toxocariasis 30.4 MRAP CRP CD40LG
12 purpura 30.4 CRP CD40LG ACE
13 fuchs' heterochromic uveitis 30.2 MRAP ACE
14 boutonneuse fever 30.2 CS CD40LG
15 hypertensive retinopathy 30.2 CRP ACE
16 melanoma-associated retinopathy 30.2 TRPM1 SAG
17 pustulosis of palm and sole 30.1 MRAP CRP
18 interstitial keratitis 30.1 MRAP CD40LG
19 asymptomatic neurosyphilis 30.0 CD40LG CD4
20 patent foramen ovale 30.0 CRP CD40LG ACE
21 cholesterol embolism 30.0 CRP ACE
22 secondary syphilis 30.0 CD40LG CD4
23 subacute bacterial endocarditis 29.9 CRP CD40LG
24 rocky mountain spotted fever 29.9 CS CD40LG
25 enthesopathy 29.9 MRAP CRP
26 cat-scratch disease 29.9 CS CRP CD40LG CD4 ACE
27 spondyloarthropathy 1 29.8 MRAP CRP CD40LG
28 chickenpox 29.8 CRP CD40LG CD4
29 tolosa-hunt syndrome 29.8 CRP ACE
30 cysticercosis 29.8 CD40LG CD4
31 eye disease 29.8 SAG RCVRN MRAP CRP CD40LG CD4
32 congenital toxoplasmosis 29.8 CD40LG CD4
33 interstitial nephritis 29.8 CRP CD40LG ACE
34 anterior scleritis 29.8 MRAP CRP
35 pulmonary embolism 29.8 CRP CD40LG ACE
36 coccidioidomycosis 29.8 CD40LG CD4
37 intracranial embolism 29.8 CRP ACE
38 retinal vasculitis 29.7 SAG MRAP CD40LG CD4 ACE
39 polyneuropathy 29.7 CRP CD40LG ACE
40 bartonellosis 29.7 CS CRP CD40LG CD4
41 granulomatous angiitis 29.7 CRP ACE
42 interval angle-closure glaucoma 29.7 RCVRN CRP
43 posterior scleritis 29.6 MRAP CRP ACE
44 acute retinal necrosis syndrome 29.6 MRAP CD40LG CD4
45 ebola hemorrhagic fever 29.6 CD40LG CD4
46 focal chorioretinitis 29.6 SAG CD40LG
47 erysipelas 29.6 CRP CD40LG
48 papilledema 29.5 CRP CD40LG CD4 ACE
49 ecthyma 29.5 CRP CD40LG
50 ocular tuberculosis 29.5 MRAP CD4 ACE

Graphical network of the top 20 diseases related to Neuroretinitis:



Diseases related to Neuroretinitis

Symptoms & Phenotypes for Neuroretinitis

Drugs & Therapeutics for Neuroretinitis

Drugs for Neuroretinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
5
Ranibizumab Approved Phase 4 347396-82-1 459903
6
Pancrelipase Approved, Investigational Phase 4 53608-75-6
7
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
8 Citrate Phase 4
9 Sildenafil Citrate Phase 4 171599-83-0
10 Antiviral Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Antibodies Phase 4
13 Immunoglobulins Phase 4
14 Phosphodiesterase Inhibitors Phase 4
15 Phosphodiesterase 5 Inhibitors Phase 4
16 Vasodilator Agents Phase 4
17 Angiogenesis Inhibitors Phase 4
18 pancreatin Phase 4
19 Vardenafil Dihydrochloride Phase 4
20
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
21
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
22
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
23
Acyclovir Approved Phase 3 59277-89-3 2022
24
Ganciclovir Approved, Investigational Phase 2, Phase 3 82410-32-0 3454
25
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
29 Molgramostim Investigational Phase 3 99283-10-0
30 Tocotrienol Investigational Phase 3 6829-55-6
31 Hormones Phase 2, Phase 3
32 Hormone Antagonists Phase 2, Phase 3
33 Mineralocorticoids Phase 2, Phase 3
34 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
35 diuretics Phase 2, Phase 3
36 Diuretics, Potassium Sparing Phase 2, Phase 3
37 Immunologic Factors Phase 3
38 Antibodies, Monoclonal Phase 2, Phase 3
39 Protective Agents Phase 3
40 Trace Elements Phase 3
41 Vitamins Phase 3
42 Nutrients Phase 3
43 Micronutrients Phase 3
44 Calciferol Phase 3
45 Antioxidants Phase 3
46 Tocotrienols Phase 3
47 Tocopherols Phase 3
48 Ganciclovir triphosphate Phase 2, Phase 3
49 Lecithin Phase 2, Phase 3
50 Retinol palmitate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 283)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
2 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
3 Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients Completed NCT00717080 Phase 4
4 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
5 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
6 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
7 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
8 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
9 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
10 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
11 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
12 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
13 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
14 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
15 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
16 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
17 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
18 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
19 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
20 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
21 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
22 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
23 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
24 Randomized Clinical Trial for Retinitis Pigmentosa Completed NCT00346333 Phase 3 Lutein
25 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa Completed NCT00000114 Phase 3 Vitamin E;Vitamin A
26 Randomized Trial for Retinitis Pigmentosa Completed NCT00000116 Phase 3 Vitamin A;Nutritional Supplement
27 Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical Results Completed NCT04224207 Phase 3
28 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
29 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
30 A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) Recruiting NCT03116113 Phase 2, Phase 3
31 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa Recruiting NCT01680510 Phase 2, Phase 3
32 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
33 The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure Active, not recruiting NCT04431882 Phase 2, Phase 3
34 A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301] Active, not recruiting NCT00999609 Phase 3
35 Safety and Efficacy of Zuretinol Acetate Oral Solution in Subjects With Inherited Retinal Disease Caused by Mutations in Retinal Pigment Epithelium Protein 65 or Lecithin:Retinol Acyltransferase Not yet recruiting NCT04311112 Phase 2, Phase 3 Placebos;ZA Low dose;ZA high dose
36 Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period Terminated NCT01786395 Phase 3 UF-021;Placebo
37 Argus® II Retinal Stimulation System Feasibility Protocol Unknown status NCT00407602 Phase 2
38 An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01914913 Phase 1, Phase 2
39 Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) Unknown status NCT02661711 Phase 2 Aflibercept
40 Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema Unknown status NCT02804360 Phase 2
41 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
42 Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial Completed NCT02609165 Phase 2 rhNGF 180 µg/ml eye drops solution;vehicle eye drops
43 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01399515 Phase 2 Valproic Acid
44 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
45 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
46 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa Completed NCT00661479 Phase 1, Phase 2 400 µg Brimonidine Tartrate Implant;200 µg Brimonidine Tartrate Implant;100 µg Brimonidine Tartrate Implant
47 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
48 A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa Completed NCT01233609 Phase 2 Valproic Acid;Placebo
49 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
50 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir

Search NIH Clinical Center for Neuroretinitis

Cochrane evidence based reviews: retinitis

Genetic Tests for Neuroretinitis

Anatomical Context for Neuroretinitis

MalaCards organs/tissues related to Neuroretinitis:

40
Retina, Eye, Testes, Bone, T Cells, Bone Marrow, Kidney

Publications for Neuroretinitis

Articles related to Neuroretinitis:

(show top 50) (show all 12513)
# Title Authors PMID Year
1
Branch retinal artery occlusion secondary to Bartonella henselae infection in a 13 year-old. 61
32435719 2020
2
Identification of a novel homozygous ARSG mutation as the second cause of Usher syndrome type 4. 61
32455177 2020
3
Rapid visual field constriction in a patient with retinitis pigmentosa and pituitary adenoma. 61
32566799 2020
4
Optical coherence tomography angiography findings in macular toxoplasma retinochoroiditis: A case report. 61
32551402 2020
5
Identification of a novel homozygous nonsense mutation in the CDHR1 gene in a Chinese family with autosomal recessive retinitis pigmentosa. 61
32277948 2020
6
Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases. 61
31997799 2020
7
Expression and purification of the heme exporter FLVCR1a. 61
32278001 2020
8
Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFRα1. 61
32362584 2020
9
Identification of novel USH2A mutations in patients with autosomal recessive retinitis pigmentosa via targeted next‑generation sequencing. 61
32319668 2020
10
Atypical Manifestations of Cat-Scratch Disease, United States, 2005-2014. 61
32568056 2020
11
Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India. 61
32277827 2020
12
Gene editing prospects for treating inherited retinal diseases. 61
31857428 2020
13
A RANDOMIZED PAIRED-EYE TRIAL OF INTRAVITREAL DEXAMETHASONE IMPLANT FOR CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA. 61
31166248 2020
14
Genetic and clinical findings in a Chinese cohort with Leber congenital amaurosis and early onset severe retinal dystrophy. 61
31630094 2020
15
Next generation sequencing using phenotype-based panels for genetic testing in inherited retinal diseases. 61
32543920 2020
16
Mapping the Neuroanatomy of ABHD16A, ABHD12, and Lysophosphatidylserines Provides New Insights into the Pathophysiology of the Human Neurological Disorder PHARC. 61
32462874 2020
17
"Myo-neuropathy" is commonly associated with mitochondrial tRNALysine mutation. 61
32577866 2020
18
Shihu Yeguang Pill protects against bright light-induced photoreceptor degeneration in part through suppressing photoreceptor apoptosis. 61
32135462 2020
19
Absence of SCAPER causes male infertility in humans and Drosophila by modulating microtubule dynamics during meiosis. 61
32527956 2020
20
Qualitative Interviews to Better Understand the Patient Experience and Evaluate Patient-Reported Outcomes (PRO) in RLBP1 Retinitis Pigmentosa (RLBP1 RP). 61
32372289 2020
21
Inner retinal preservation in the photoinducible I307N rhodopsin mutant mouse, a model of autosomal dominant retinitis pigmentosa. 61
31811649 2020
22
Neuroretinitis: a tricky mimic. 61
32546515 2020
23
Bartonella neuroretinitis (cat-scratch disease). 61
32546517 2020
24
Efficacy of Intravitreal Aflibercept Injections in the Treatment of Idiopathic Retinal Vasculitis, Aneurysms and Neuroretinitis Syndrome. 61
32541433 2020
25
Use of augmented reality technology for improving visual acuity of individuals with low vision. 61
32461448 2020
26
Expanding the clinical and phenotypic heterogeneity associated with biallelic variants in ACO2. 61
32519519 2020
27
Genotype-phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome. 61
32077159 2020
28
T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Familial Hemophagocytic Lymphohistiocytosis Who Do Not Have Matched Family Donors: Experience in Oman. 61
32088369 2020
29
Optical coherence tomography in the evaluation of retinitis pigmentosa. 61
32552399 2020
30
Genetic, Anatomical, and Functional Correlation of Sector Retinitis Pigmentosa. 61
32525539 2020
31
Cytomegalovirus retinitis in an immunocompetent host after complicated cataract surgery. 61
32309678 2020
32
Select pediatric vitreoretinal disease in the setting of Turner's syndrome. 61
32274445 2020
33
An update on retinal prostheses. 61
31866339 2020
34
Acute retinal necrosis: Clinical manifestation and long-term visual outcomes in a series of polymerase chain reaction-positive patients. 61
32567354 2020
35
Chronic Granulomatous Disease with the McLeod Phenotype: a French National Retrospective Case Series. 61
32562208 2020
36
Management of Full-Thickness Macular Hole in A Genetically Confirmed Case with Usher Syndrome. 61
32566994 2020
37
Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles. 61
31909088 2020
38
Opsins for vision restoration. 61
31982136 2020
39
Retinal morphology in Astyanax mexicanus during eye degeneration. 61
31811648 2020
40
Next-generation sequencing-based clinical diagnosis of choroideremia and comprehensive mutational and clinical analyses. 61
32487042 2020
41
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. 61
32482069 2020
42
Living with type I Usher syndrome: insights from patients and their parents. 61
32367747 2020
43
Mutations in the Kinesin-2 Motor KIF3B Cause an Autosomal-Dominant Ciliopathy. 61
32386558 2020
44
Novel compound heterozygous EYS variants may be associated with arRP in a large Chinese pedigree. 61
32436957 2020
45
Human Mesenchymal Stem Cell Secretome Exhibits a Neuroprotective Effect over In Vitro Retinal Photoreceptor Degeneration. 61
32514411 2020
46
Evaluation of the genetic association between early-onset primary angle-closure glaucoma and retinitis pigmentosa. 61
32562694 2020
47
Deep Learning-Based Detection of Pigment Signs for Analysis and Diagnosis of Retinitis Pigmentosa. 61
32570943 2020
48
Validation of a vision-related activity scale for patients with retinitis pigmentosa. 61
32571342 2020
49
Transorbital electrical stimulation in retinitis pigmentosa. Better results joining visual pattern stimulation? 61
32497738 2020
50
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa. 61
32573764 2020

Variations for Neuroretinitis

Expression for Neuroretinitis

Search GEO for disease gene expression data for Neuroretinitis.

Pathways for Neuroretinitis

Pathways related to Neuroretinitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 SAG RCVRN CRP

GO Terms for Neuroretinitis

Biological processes related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of calcium ion transport GO:0051924 8.62 RCVRN CD4

Sources for Neuroretinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....